Alphamab Approved to Start US Trials of PD-L1/CTLA-4 Bispecific

Jiangsu Alphamab Oncology was approved to start a US Phase II trial of its  PD-L1/CTLA-4 bispecific antibody in patients with thymic carcinoma, a rare disease. Alphamab said inoperable or metastatic thymic carcinoma, although rare, is highly aggressive with no approved treatments. In an Australian Phase I trial, KN046 showed a 75% disease response rate and 100% disease control rate in patients with the disease. Alphamab has already dosed the first thymic carcinoma patient in a pivotal China Phase II trial. More details.... Stock Symbol: (HK: 9966) Share this with colleagues: // //